Determination of phage susceptibility as a clinical diagnostic tool: A routine perspective.

clinical microbiology diagnosis personalized medicine phage (bacteriophage) susceptibility

Journal

Frontiers in cellular and infection microbiology
ISSN: 2235-2988
Titre abrégé: Front Cell Infect Microbiol
Pays: Switzerland
ID NLM: 101585359

Informations de publication

Date de publication:
2022
Historique:
received: 22 07 2022
accepted: 30 08 2022
entrez: 10 10 2022
pubmed: 11 10 2022
medline: 12 10 2022
Statut: epublish

Résumé

As the global burden of disease caused by multidrug resistant bacteria is a major source of concern, credible clinical alternatives to antibiotic therapy, such as personalized phage therapy, are actively explored. Although phage therapy has been used for more than a century, the issue of an easy to implement diagnostic tool for determining phage susceptibility that meets current routine clinical needs is still open. In this Review, we summarize the existing methods used for determining phage activity on bacteria, including the three reference methods: the spot test, the double agar overlay plaque assay, and the Appelmans method. The first two methods rely on the principle of challenging the overnight growth of a lawn of bacteria in an agar matrix to a known relative phage to bacteria concentration and represent good screening tools to determine if the tested phage can be used for a "passive" and or "active" treatment. Beside these methods, several techniques, based on "real-time" growth kinetics assays (GKA) have been developed or are under development. They all monitor the growth of clinical isolates in the presence of phages, but use various detection methods, from classical optical density to more sophisticated techniques such as computer-assisted imagery, flow-cytometry, quantitative real-time polymerase chain reaction (qPCR) or metabolic indicators. Practical considerations as well as information provided about phage activity are reviewed for each technique. Finally, we also discuss the analytical and interpretative requirements for the implementation of a phage susceptibility testing tool in routine clinical microbiology.

Identifiants

pubmed: 36211951
doi: 10.3389/fcimb.2022.1000721
pmc: PMC9532704
doi:

Substances chimiques

Anti-Bacterial Agents 0
Agar 9002-18-0

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1000721

Informations de copyright

Copyright © 2022 Daubie, Chalhoub, Blasdel, Dahma, Merabishvili, Glonti, De Vos, Quintens, Pirnay, Hallin and Vandenberg.

Déclaration de conflit d'intérêts

The handling editor GR declared a past co-authorship with the author(s) MM, JP and BB.

Références

Lancet Infect Dis. 2010 Sep;10(9):597-602
pubmed: 20705517
Appl Microbiol Biotechnol. 2011 May;90(3):851-9
pubmed: 21491205
Sci Rep. 2017 Apr 12;7:46151
pubmed: 28401893
Trends Microbiol. 2010 Jan;18(1):20-9
pubmed: 19896852
Biomed Res Int. 2014;2014:319351
pubmed: 25530959
Microbiol Mol Biol Rev. 2000 Mar;64(1):69-114
pubmed: 10704475
Pharm Res. 2011 Apr;28(4):934-7
pubmed: 21063753
Antibiotics (Basel). 2019 Aug 23;8(3):
pubmed: 31443585
Bacteriophage. 2011 Mar;1(2):66-85
pubmed: 22334863
Clin Microbiol Rev. 2019 Jan 16;32(2):
pubmed: 30651225
Sci Rep. 2019 Jul 5;9(1):9788
pubmed: 31278344
Future Microbiol. 2007 Oct;2(5):485-91
pubmed: 17927471
EBioMedicine. 2016 Jan 05;4:124-37
pubmed: 26981577
AIMS Microbiol. 2017 Aug 4;3(3):649-688
pubmed: 31294181
Methods Mol Biol. 2009;501:69-76
pubmed: 19066811
Viruses. 2022 Jul 07;14(7):
pubmed: 35891470
Viruses. 2018 Apr 05;10(4):
pubmed: 29621199
Front Microbiol. 2020 Nov 17;11:547458
pubmed: 33281753
Lancet Infect Dis. 2021 Mar;21(3):427-436
pubmed: 32949500
Nature. 1999 Jun 10;399(6736):541-8
pubmed: 10376593
FEMS Microbiol Rev. 2020 Nov 24;44(6):684-700
pubmed: 32472938
Viruses. 2019 Mar 11;11(3):
pubmed: 30862096
ISME J. 2010 Jun;4(6):739-51
pubmed: 20147985
Antibiotics (Basel). 2022 Jan 27;11(2):
pubmed: 35203767
BMC Microbiol. 2019 Jun 17;19(1):134
pubmed: 31208333
Antibiotics (Basel). 2020 Jul 04;9(7):
pubmed: 32635429
Front Microbiol. 2020 Dec 18;11:602444
pubmed: 33391221
Bacteriophage. 2012 Jul 1;2(3):159-167
pubmed: 23275867
Genetics. 2000 Oct;156(2):471-6
pubmed: 11014798
Burns. 2019 Feb;45(1):260
pubmed: 30527641
Bacteriophage. 2016 Jan 5;6(1):e1096995
pubmed: 27144083
PLoS One. 2021 Mar 23;16(3):e0248917
pubmed: 33755710
Methods Mol Biol. 2009;501:175-202
pubmed: 19066822
Viruses. 2018 Feb 06;10(2):
pubmed: 29415431
Lancet Infect Dis. 2022 Aug;22(8):e208-e220
pubmed: 35248167
AIMS Microbiol. 2020 Jul 22;6(3):204-230
pubmed: 33134741
Lancet Infect Dis. 2019 Jan;19(1):35-45
pubmed: 30292481
PLoS One. 2015 Mar 11;10(3):e0118557
pubmed: 25761060
Viruses. 2018 Apr 12;10(4):
pubmed: 29649135
Adv Virus Res. 2012;83:73-121
pubmed: 22748809
Antimicrob Agents Chemother. 2001 Mar;45(3):649-59
pubmed: 11181338

Auteurs

Valéry Daubie (V)

Innovation and Business Development Unit, LHUB-ULB, Université Libre de Bruxelles, Brussels, Belgium.
Department of Microbiology, LHUB-ULB, Université Libre de Bruxelles, Brussels, Belgium.

Houssein Chalhoub (H)

Innovation and Business Development Unit, LHUB-ULB, Université Libre de Bruxelles, Brussels, Belgium.
Centre for Environmental Health and Occupational Health, School of Public Health, Université Libre de Bruxelles (ULB), Brussels, Belgium.

Bob Blasdel (B)

R&D department, Vesale Bioscience, Noville-sur-Mehaigne, Belgium.

Hafid Dahma (H)

Department of Microbiology, LHUB-ULB, Université Libre de Bruxelles, Brussels, Belgium.

Maya Merabishvili (M)

Laboratory for Molecular and Cellular Technology, Queen Astrid Military Hospital, Brussels, Belgium.

Tea Glonti (T)

Laboratory for Molecular and Cellular Technology, Queen Astrid Military Hospital, Brussels, Belgium.

Nathalie De Vos (N)

Department of Clinical Chemistry, LHUB-ULB, Université Libre de Bruxelles, Brussels, Belgium.

Johan Quintens (J)

R&D department, Vesale Bioscience, Noville-sur-Mehaigne, Belgium.

Jean-Paul Pirnay (JP)

Laboratory for Molecular and Cellular Technology, Queen Astrid Military Hospital, Brussels, Belgium.

Marie Hallin (M)

Centre for Environmental Health and Occupational Health, School of Public Health, Université Libre de Bruxelles (ULB), Brussels, Belgium.

Olivier Vandenberg (O)

Innovation and Business Development Unit, LHUB-ULB, Université Libre de Bruxelles, Brussels, Belgium.
Centre for Environmental Health and Occupational Health, School of Public Health, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Division of Infection and Immunity, Faculty of Medical Sciences, University College London, London, United Kingdom.

Articles similaires

Vancomycin-associated DRESS demonstrates delay in AST abnormalities.

Ahmed Hussein, Kateri L Schoettinger, Jourdan Hydol-Smith et al.
1.00
Humans Drug Hypersensitivity Syndrome Vancomycin Female Male
Humans Arthroplasty, Replacement, Elbow Prosthesis-Related Infections Debridement Anti-Bacterial Agents
Genome, Viral Ralstonia Composting Solanum lycopersicum Bacteriophages
Vancomycin Polyesters Anti-Bacterial Agents Models, Theoretical Drug Liberation

Classifications MeSH